Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, Leonardi GC, Plodkowski AJ, Gupta H, Cherniack AD, Tolstorukov MY, Sharma B, Felt KD, Gainor JF, Ravi A, Getz G, Schalper KA, Henick B, Forde P, Anagnostou V, Jänne PA, Van Allen EM, Nishino M, Sholl LM, Christiani DC, Lin X, Rodig SJ, Hellmann MD, Awad MM. Ricciuti B, et al. JAMA Oncol. 2022 Aug 1;8(8):1160-1168. doi: 10.1001/jamaoncol.2022.1981. JAMA Oncol. 2022. PMID: 35708671 Free PMC article.
The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G, Ricciuti B, Brambilla M, Baglivo S, Soli I, Minenza E, Leonardi GC, D'arpino A, Colabrese D, Tazza M, Zicari D, Minotti V, Chiari R. Metro G, et al. Among authors: ricciuti b. Expert Opin Drug Saf. 2017 Jan;16(1):101-109. doi: 10.1080/14740338.2017.1267725. Epub 2016 Dec 11. Expert Opin Drug Saf. 2017. PMID: 27910704 Review.
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R. Ricciuti B, et al. J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485. doi: 10.1007/s00432-018-2805-3. Epub 2018 Dec 1. J Cancer Res Clin Oncol. 2019. PMID: 30506406
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM. Aguilar EJ, et al. Among authors: ricciuti b. Ann Oncol. 2019 Oct 1;30(10):1653-1659. doi: 10.1093/annonc/mdz288. Ann Oncol. 2019. PMID: 31435660 Free article.
150 results